NGN Capital

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Valtech Cardio Ltd. is a medical device company based in Or Yehuda, Israel, founded in 2006. It specializes in the development and manufacturing of cardiovascular devices aimed at treating mitral and tricuspid valve regurgitation through minimally invasive techniques. The company’s flagship products include the Cardioband System, which reconstructs the mitral valve via transfemoral direct annuloplasty, and the Cardiovalve system, designed for transfemoral transseptal mitral valve replacement. Additionally, Valtech offers the Cardinal, an adjustable annuloplasty ring that allows surgeons to optimize valve repair during surgery. The company is also advancing its pipeline with products like Cardioband Tricuspid, aimed at mitral regurgitation treatment, and the V-Chordal, which addresses mitral valve prolapse. Valtech Cardio operates as a subsidiary of Zeppelin Zox Ltd.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

SpineView is a medical device company that specializes in developing and commercializing surgical and interventional products for spine-related procedures, particularly focusing on spinal decompression and fusion applications. Founded in 2005 and headquartered in Fremont, California, the company offers a range of minimally invasive surgical tools, including the flex Minimally Invasive Surgical discectomy system, which aids in discectomy and endplate preparation. Additionally, SpineView provides an MIS decompression system that enhances access and visualization during surgical procedures on the cervical, thoracic, or lumbar spine, accompanied by various surgical instruments. The enSpire Interventional Discectomy System, another key product, is designed for cutting, grinding, and aspirating disc tissue during lumbar discectomy procedures. SpineView distributes its products through a network of distributors to support healthcare providers in spinal surgery.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in the development of non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Founded in 2004, BeneChill's flagship product, the RhinoChill System, is designed to effectively reduce patient temperature, which is critical in improving survival rates and recovery in critical care settings. The company's innovative approach addresses a significant need in the healthcare sector by providing advanced solutions that support patient care during life-threatening situations.

Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Cerapedics, Inc. is an orthobiologics company specializing in the development and commercialization of innovative synthetic small peptide technologies for bone healing. Founded in 2000 and headquartered in Westminster, Colorado, with an additional office in Denver, the company offers products such as i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural healing process in orthopedic applications, and i-FACTOR+ MATRIX for surgical implantation. Cerapedics focuses on creating biomimetic solutions, specifically its proprietary small peptide molecule (P-15), aimed at improving outcomes in spinal fusion surgery and other orthopedic procedures. The company's technology strives to provide safer and more predictable bone formation compared to traditional bone growth factors.

Vivaldi Biosciences is a clinical-stage biotechnology company focused on developing live attenuated influenza vaccines (LAIVs) for both seasonal and pandemic influenza. Founded in 2006, the company is based in Fort Collins, Colorado. Vivaldi's portfolio includes deltaFLU, an advanced self-adjuvanting influenza vaccine administered as a nasal spray. Additionally, the company is engaged in developing therapeutics through a small molecule program targeting the NS1 protein of influenza.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.

ACT Biotech is a biotechnology company dedicated to the development and commercialization of innovative therapies for cancer, particularly in underserved disease areas where patient needs are significant. With a seasoned international leadership team and extensive expertise in clinical development, ACT is well-equipped to advance its promising portfolio of pre-clinical drug candidates. The company has implemented a focused development strategy aimed at accelerating the delivery of therapeutic tools to meet the needs of cancer patients. Its strengths in stability and experienced leadership create opportunities for corporate partnerships that can further advance its validated drug compounds. Through these efforts, ACT Biotech aims to make a meaningful impact in the fight against cancer.

Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

BeneChill, Inc. is a medical device company based in San Diego, California, specializing in the development of non-invasive cooling technologies aimed at enhancing patient outcomes following acute ischemic events, including cardiac arrest, stroke, and traumatic brain injury. Founded in 2004, BeneChill's flagship product, the RhinoChill System, is designed to effectively reduce patient temperature, which is critical in improving survival rates and recovery in critical care settings. The company's innovative approach addresses a significant need in the healthcare sector by providing advanced solutions that support patient care during life-threatening situations.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

Nitec is a specialty pharmaceutical company focused on the commercialization and development of medicines to treat chronic inflammation and pain-related diseases. It seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets. The Company is a spin-out of Merck KGaA and is headquartered in the Basel region of Switzerland. Since its formation in 2004, Nitec has developed and commercialized its lead product, Lodotra™. Nitecâ€:tm:s most advanced product candidate is Lodotra™, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. In January 2009, Lodotra™ was recommended for European regulatory approval for the treatment of rheumatoid arthritis (“RA“), particularly the associated and debilitating morning stiffness, following the successful completion of a phase III trial (CAPRA-1) in 2006. Germany was the Reference Member State and Lodotra™ is now also expected approvable by the regulatory agencies of 14 other countries under the Decentralized Procedure. In March Nitec announced a European partnership for Lodotraâ€:tm:s commercialization with MundiPharma. Merck KGaA, which holds the distribution rights to Lodotra™ in Germany and Austria, have recently launched the product in Germany. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra™ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra™ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR). Nitecâ€:tm:s second product candidate is TruNoc™ (tarenflurbil), which is being developed as a treatment of neuropathic pain and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Artisan Pharma, Inc., a biopharmaceutical company, provides critical-care and hospital-based therapeutics to patients, treating physicians, and payors in the United States and internationally. It offers ART-123, a novel, recombinant, and soluble thrombomodulin for the treatment of disseminated intravascular coagulation in sepsis. The company offers its products in Japan, China, Taiwan, and Korea. It has a strategic manufacturing alliance with A-Bio Pharma Pte Ltd. Artisan Pharma, Inc. was formerly known as Artisan Therapeutics, Inc. and changed its name to Artisan Pharma, Inc. in September 2006. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

EKOS Corporation is a pioneering developer of ultrasound accelerated thrombolysis, specializing in the treatment of vascular thrombosis. Since its inception in 2005, the company has introduced the EkoSonic Endovascular System, which is utilized by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions globally. This innovative system facilitates faster, safer, and more complete dissolution of thrombus through controlled and selective infusion of physician-specified fluids, significantly enhancing the efficacy of thrombolytic therapies.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Small Bone Innovations (SBi) is a medical device company specializing in the design, manufacture, and distribution of implants tailored for small bones and joints. Their product portfolio focuses on trauma and arthroplasty applications, catering specifically to the thumb, hand, wrist, elbow, foot, and ankle regions. SBi's offerings include basal joint arthritis treatments and implants designed to replace anatomic joint surfaces while preserving bones and minimizing disruption to collateral ligaments and soft tissues.

Javelin Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products for the pain management market primarily in the United States and Europe. Its products focus on treating various pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain (orthopedic injury pain), procedural pain, and burn pain. The company's Dyloject (injectable diclofenac) received approval for marketing to treat post-operative pain in the United Kingdom and was licensed to Therabel Pharma N.V. for commercialization in the European Union and certain other countries outside the United States. Its products in the Phase 3 development stage in the U.S. include Dyloject (diclofenac sodium injectable), an injectable formulation of diclofenac and a prescription nonsteroidal anti-inflammatory drug that is used to treat post-operative pain due to its combination of effectiveness and tolerability; Ereska (intranasal ketamine), a proprietary nasal formulation; and Rylomine (intranasal morphine) for treatment of acute moderate-to-severe pain, including breakthrough pain. Javelin Pharmaceuticals has license agreements with Shimoda Biotech, Ltd. to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac; and West Pharmaceutical Services, Inc. to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.

OptiScan Biomedical Corporation, founded in 1994 and located in Hayward, California, specializes in developing bedside blood monitoring systems for critically ill patients in intensive care units (ICUs). The company's flagship product, the OptiScanner 5000, is an automated glucose monitoring platform that utilizes spectroscopy technology to measure plasma glucose levels directly, eliminating the need for calibration. This system enables healthcare providers to rapidly detect changes in glucose levels, thus supporting better management of critically ill patients' health.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

EKOS Corporation is a pioneering developer of ultrasound accelerated thrombolysis, specializing in the treatment of vascular thrombosis. Since its inception in 2005, the company has introduced the EkoSonic Endovascular System, which is utilized by interventional radiologists, cardiologists, and vascular surgeons at leading medical institutions globally. This innovative system facilitates faster, safer, and more complete dissolution of thrombus through controlled and selective infusion of physician-specified fluids, significantly enhancing the efficacy of thrombolytic therapies.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.